Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06290505 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study

Study acronym: PALEO
StatusRecruiting
PhasePhase 2
Started2021-12-08
View on ClinicalTrials.gov ↗
The purpose of this study is to investigate the effects of the addition of the stereotactic body radiotherapy and durvalumab to a well tolerated 2 week chemotherapy and radiation treatment regimen in people with esophageal cancer that is locally advanced or has spread to another area of the body (metastasized).

Amendment record

Amended 6 times since 2024-02-26; most recent filed 2026-05-05. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-30.

2026-05-05
Amendment Study Status, Contacts/Locations v6
2025-07-22
Amendment Study Status, Contacts/Locations v5
2025-07-07
Amendment Study Status, Contacts/Locations v4
2024-10-31
Amendment Study Status, Study Description v3
2024-10-30
Amendment Study Status, Study Description, Conditions, Arms and Interventions, Outcome Measures, Eligibility, Contacts/Locations v2
2024-08-28
Amendment Study Status, Contacts/Locations v1
2024-02-26
Original filing
Trial Details
NCT Number NCT06290505
Lead Sponsor Australasian Gastro-Intestinal Trials Group
Conditions Esophageal Cancer
Enrollment 54 participants
Start Date 2021-12-08
Primary Completion 2027-07-31 (estimated)
Study Completion 2029-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-08